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Risk of acute myocardial infarction with NSAIDs in real world use: 
bayesian meta-analysis of individual patient data
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Edeltraut Garbe,6 James M Brophy2,4,7  
ABSTRACT
ObjeCtive
To characterise the determinants, time course, and 
risks of acute myocardial infarction associated with 
use of oral non-steroidal anti-inflammatory drugs 
(NSAIDs).
Design
Systematic review followed by a one stage bayesian 
individual patient data meta-analysis.
Data sOurCes
Studies from Canadian and European healthcare 
databases.
review methODs
Eligible studies were sourced from computerised drug 
prescription or medical databases, conducted in the 
general or an elderly population, documented acute 
myocardial infarction as specific outcome, studied 
selective cyclo-oxygenase-2 inhibitors (including 
rofecoxib) and traditional NSAIDs, compared risk of 
acute myocardial infarction in NSAID users with 
non-users, allowed for time dependent analyses, and 
minimised effects of confounding and 
misclassification bias. 
expOsure anD OutCOmes
Drug exposure was modelled as an indicator variable 
incorporating the specific NSAID, its recency, duration 
of use, and dose. The outcome measures were the 
summary adjusted odds ratios of first acute myocardial 
infarction after study entry for each category of NSAID 
use at index date (date of acute myocardial infarction 
for cases, matched date for controls) versus non-use in 
the preceding year and the posterior probability of 
acute myocardial infarction.
results
A cohort of 446 763 individuals including 61 460 with 
acute myocardial infarction was acquired. Taking any 
dose of NSAIDs for one week, one month, or more than 
a month was associated with an increased risk of 
myocardial infarction. With use for one to seven days 
the probability of increased myocardial infarction risk 
(posterior probability of odds ratio >1.0) was 92% for 
celecoxib, 97% for ibuprofen, and 99% for diclofenac, 
naproxen, and rofecoxib. The corresponding odds 
ratios (95% credible intervals) were 1.24 (0.91 to 1.82) 
for celecoxib, 1.48 (1.00 to 2.26) for ibuprofen, 1.50 
(1.06 to 2.04) for diclofenac, 1.53 (1.07 to 2.33) for 
naproxen, and 1.58 (1.07 to 2.17) for rofecoxib. Greater 
risk of myocardial infarction was documented for 
higher dose of NSAIDs. With use for longer than one 
month, risks did not appear to exceed those 
associated with shorter durations.
COnClusiOns
All NSAIDs, including naproxen, were found to be 
associated with an increased risk of acute myocardial 
infarction. Risk of myocardial infarction with celecoxib 
was comparable to that of traditional NSAIDS and was 
lower than for rofecoxib. Risk was greatest during the 
first month of NSAID use and with higher doses.
Introduction
It is generally accepted that oral non-steroidal anti-in-
flammatory drugs (NSAIDs) can increase the risk of 
acute myocardial infarction. Randomised controlled 
trials of NSAIDs have been of limited use for assessing 
this rare adverse event, as they had small cohorts and 
poor generalisability.1 2  The trials excluded those at 
highest cardiovascular risk or with established cardio-
vascular disease.3 4  Network meta-analyses of ran-
domised controlled trials of NSAIDs and myocardial 
infarction risk have attempted to improve statistical 
power, but the results of direct and indirect compari-
sons of NSAIDs and placebo remain imprecise and 
occasionally inconclusive.3 4
The Prospective Randomized Evaluation of Celecoxib 
Integrated Safety vs. Ibuprofen Or Naproxen (PRECI-
SION) trial was a large randomised controlled trial 
(n=24 081) that filled some of these knowledge gaps. 
This trial’s conclusion of the non-inferiority of moder-
ate dose celecoxib compared with ibuprofen and 
naproxen on a primary composite outcome of cardio-
vascular death, non-fatal myocardial infarction, or 
non-fatal stroke in patients with arthritis at moderate 
cardiovascular risk has challenged the convention that 
all selective cyclo-oxygenase-2 (COX 2) inhibitors share 
the same heightened cardiovascular risk as rofecoxib 
and that naproxen has superior cardiovascular safety.5
WhAT IS AlReAdy knoWn on ThIS TopIC
Evidence suggests that both traditional and cyclo-oxygenase-2 selective non-
steroidal anti-inflammatory drugs (NSAIDs) can increase the risk of acute 
myocardial infarction 
The timing of the risk, the effect of dose, treatment duration, and the comparative 
risks between NSAIDs are poorly understood
WhAT ThIS STudy AddS
Using a bayesian meta-analysis of individual patient data and studying real world 
settings, it is shown that all traditional NSAIDs, including naproxen, appear to be 
associated with an increased risk of acute myocardial infarction
The risk with celecoxib does not seem to be greater than that with traditional 
NSAIDs. Onset of risk occurs in the first week
Short term use for 8-30 days at a high daily dose (celecoxib >200 mg, diclofenac 
>100 mg, ibuprofen >1200 mg, and naproxen >750 mg) is associated with the 
greatest harms, without obvious further increases in risk beyond the first 30 days
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Although the PRECISION trial reported on myocar-
dial infarction as a secondary outcome, it did not 
include a comparison with placebo and cannot inform 
on the comparative cardiovascular safety of NSAIDs 
other than as studied; this trial enrolled patients 
 receiving standardised, fixed daily doses of NSAIDs for 
arthritis.5  Dosages and treatment duration in this and 
other NSAID randomised controlled trials3 4  may not 
represent the clinical reality of many patients who use 
these drugs in low or varying doses, or intermittently, 
and often switch between various NSAIDs.6 7  Risk of 
acute myocardial infarction associated with NSAIDs 
should be further characterised by pooling population 
based observational studies since these better reflect 
how NSAIDs are used in practice.8
We performed an individual patient data meta-analy-
sis of studies from healthcare databases to determine 
the time course for risk of acute myocardial infarction 
and the effects of dose and of duration of continuous 
use for the main NSAIDs. The study was designed to 
capture the complex time varying nature of NSAID use. 
We verified that measurement of NSAID exposure was 
adequate for addressing the objectives of this study 
then examined various aspects of exposure that are rel-
evant to the myocardial infarction outcome, including 
recency of use and the combined effect of dose and 
duration. To optimise the power to make useful clinical 
inferences we studied a large patient sample.
Methods
systematic review
Two researchers developed literature search strategies 
and selected studies (MB, JMB). We searched Medline, 
Embase, and PubMed by applying filters for retrieval of 
observational studies and by combining these with the 
appropriate search terms for non-steroidal anti-inflam-
matory drugs (NSAIDs) and for myocardial infarction 
(see table 1 in web appendix 1). We also retrieved sys-
tematic reviews of non-randomised studies of cardio-
vascular adverse events associated with NSAIDs and 
manually searched their bibliography. To increase sen-
sitivity for the myocardial infarction outcome, we 
included broader terms for cardiac morbidity. After an 
initial search, we set up weekly updates from June 2010 
to November 2013.
study selection and risk of bias assessment
We assessed the appropriateness of each study for 
meeting the objectives and design of this individual 
patient data (IPD) meta-analysis. Firstly, we selected 
studies that documented acute myocardial infarction 
separately from other cardiovascular outcomes, com-
pared the risk of acute myocardial infarction in NSAID 
users with non-users, considered traditional and COX 2 
selective NSAIDs separately, were conducted in the gen-
eral or an elderly population, allowed for analyses cor-
responding to exposure time windows of interest, and 
minimised the effects of confounding by indication or 
by contraindication and of selective prescribing. This 
last criterion was implemented by limiting the inclu-
sion of studies to those that were conducted before 
rofecoxib was withdrawn from the market, matched 
cases and controls for calendar time, and documented 
comorbidities and concomitant treatments. Secondly, 
we checked that the study was suitable for characteris-
ing the time course of myocardial infarction risk and the 
dose and duration effects of NSAIDs.
Data sources
The full text of 82 studies was screened for eligibility. Of 
these, we excluded 67 on the basis of one or more of the 
criteria outlined previously. Of the 15 studies eligible for 
further consideration, seven were excluded because the 
definition of exposed time precluded valid pooling of 
patient level data, whereas permission to access IPD 
was not obtained for another four studies. In web 
appendix 1, figure 1 shows the study flow and tables 2 to 4 
the reasons for exclusion of studies.
We created a nested case-control dataset to serve as 
reference for harmonising the IPD. For the reference 
dataset (RAMQ) we used data from the universal, com-
puterised public insurance database of Quebec, Can-
ada. The other datasets available for IPD meta-analysis 
were a population based case-control study from Fin-
land9  (Finland) and two nested case-control studies, 
one from the UK using data from the General Practice 
Research Database (GPRD)10  and the other from Canada 
using data from Saskatchewan (see table 1 in web 
appendix 2).11  All source databases have been exten-
sively used in pharmacoepidemiology12-15  and were val-
idated for the study of coronary heart disease or acute 
myocardial infarction.16-20
Common data structure
Outcome
In all studies, the index date was the date of hospital 
admission with acute myocardial infarction for cases 
and a time matched date for controls. The similarity of 
definition and ascertainment of cases and controls in 
each study see (table 2 in web appendix 2) confirmed 
the appropriateness of pooling in a meta-analysis.
NSAID exposure and confounders
The IPD were drawn from the elderly (≥65 years) and 
general populations in the RAMQ and Finland studies, 
respectively (approximately 200 000 individuals each). 
For the GPRD and Saskatchewan studies the IPD were 
drawn from the general population (approximately 
20 000 individuals each). As a preliminary step, we 
defined a common structure for exposures and con-
founders to allow for retrospective harmonisation of the 
data.21  The harmonisation framework ensured that 
studies were clinically and methodologically similar 
and that patient level data across studies were suffi-
ciently compatible to allow valid data integration.22
The NSAIDs of interest were celecoxib, the three main 
traditional NSAIDs (diclofenac, ibuprofen, and 
naproxen), and rofecoxib. We captured time varying 
NSAID use, working with the original study (see table 3 
in web appendix 2), to create several multidimensional 
categories with different indicator variables represent-
ing the contribution of recency of use (past, recent, or 
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current), dose level (low or high), and treatment dura-
tion for mutually exclusive time windows (fig 1). We ver-
ified that the NSAID use categories in each dataset were 
inferentially equivalent such that pooling across stud-
ies was justified.
On the basis of substantive knowledge and confir-
mation by a search of the literature,23-26  we identified 
risk factors for the outcome and potential confound-
ers, which formed a set of candidate covariates to 
include in multivariable regression analysis. Using a 
simplified causal graph,27  we mapped relations 
between variables,28  including the special case of 
time dependent confounders that are mediating inter-
mediates on the causal pathway between NSAID expo-
sure and the acute myocardial infarction outcome (see 
fig 1 in web appendix 2).29 Such mediator variables 
must be identified at the planning stage of analysis as 
they require appropriate measurement and analytical 
strategies. We then substantiated the confounder sta-
tus for each candidate covariate by calculating the 
odds ratio of association between the covariate and 
exposure to NSAIDs among controls and the odds 
ratio of association between the covariate and myo-
cardial infarction outcome in the unexposed. This led 
to the final set of target confounders (or IPD meta-anal-
ysis confounders) selected for adjustment in the 
meta-analysis: age at index date, male sex, diabetes, 
hyperlipidaemia, hypertension, previous myocardial 
infarction, coronary heart disease (excluding previous 
myocardial infarction), congestive heart failure, cere-
brovascular disease, peripheral vascular disease, 
chronic obstructive pulmonary disease, gastrointesti-
nal ulcer disease, gastrointestinal bleed, acute or 
chronic renal failure, rheumatoid arthritis, and con-
comitant treatment with oral corticosteroids, clopido-
grel, or cardioprotective aspirin. All studies were 
adjusted for the following IPD meta-analysis con-
founders that were common to all studies (or common 
IPD meta-analysis confounders): age at index date, 
diabetes, hyperlipidaemia, hypertension, coronary 
heart disease, and rheumatoid arthritis. Each study 
was also adjusted for other IPD meta-analysis con-
founders if available in the original study dataset (see 
table 2 in web appendix 2). When an IPD meta-analy-
sis confounder was unavailable, it was missing sys-
tematically for all subjects in that study.
statistical analysis
The available data for the IPD meta-analysis were gath-
ered at two levels. At the higher level of analysis are the 
characteristics of the four studies. At the lower level are 
individual patient characteristics. For pooling IPD, we 
opted for a one stage model in the bayesian framework. 
Such a model has a hierarchical structure allowing the 
IPD to be combined in one step while accounting for 
clustering of data within each database study.30 31
In bayesian analysis, combining prior information 
with the available data yields a posterior probability 
distribution for each parameter of interest. To avoid 
undue influence on posterior estimates of non-informa-
tive priors for the between study variance, especially 
since only four studies were available,32 33  we selected a 
range of reasonably informative priors based on histor-
ical information.34 35  In a comprehensive recent 
meta-analysis of observational studies, the odds ratio of 
acute myocardial infarction with a given NSAID gener-
ally varied by up to fourfold across studies and sub-
group analyses.36  For the primary analysis, the between 
study standard deviation on the log odds ratio, τ, was 
assigned a half normal prior distribution (to represent a 
prior belief that although the true odds ratios of 95% of 
studies could span a fourfold range, less heterogeneity 
is more likely).34 For the pooled (log) odds ratio esti-
mates of acute myocardial infarction for each exposure, 
we used a non-informative normal prior distribution 
(mean 0, variance 10−6).
A few exposure categories in the Finland and GPRD 
studies and certain IPD meta-analysis confounders in 
studies other than from RAMQ were missing systemati-
cally. We assumed that it was plausible for systemati-
cally missing variables to be missing completely at 
random.37 We specified random effects for each multidi-
mensional indicator category of NSAID use. As appro-
priate for each study design (RAMQ and GPRD: 
individually matched nested case-control studies; Fin-
land: population based matched case-control study; 
Saskatchewan: frequency matched nested case-control 
study), we implemented conditional (RAMQ, Finland, 
and GPRD) or unconditional logistic regression (Sas-
katchewan) to analyse the IPD. For each exposure, we 
obtained from the posterior distribution the median 
value of the odds ratio of acute myocardial infarction 
with its 95% credible intervals adjusted for the IPD 
meta-analysis confounders available in each study. We 
report summary adjusted odds ratios for each exposure 
category, with non-use of any NSAIDs in the year pre-
ceding the index date as the reference category.
Index date (days)
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Non-use Past Recent Current
-30 -1 0
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High
Current use at high dose for >30 days
Current use at low dose for >30 days
Current use at high dose for 8-30 days
Current use at low dose for 8-30 days
Current use at any dose for 1-7 days
Recent use at any dose
Past use at any dose
Non-use
Celecoxib (low dose ≤200 mg, high dose >200 mg)
Diclofenac (low dose ≤100 mg, high dose >100 mg)
Ibuprofen (low dose ≤1200 mg, high dose >1200 mg)
Naproxen (low dose ≤750 mg, high dose >750 mg)
Rofecoxib (low dose ≤25 mg, high dose >25 mg)
Fig 1 | multidimensional indicator categories of non-steroidal anti-inflammatory drug 
(nsaiD) use defined by recency of use, daily dose, and duration
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The bayesian framework allows for the making of 
direct probability statements, based on posterior distri-
butions. For exposures corresponding to current use for 
each NSAID, we obtained probabilities that the sum-
mary adjusted odds ratio of acute myocardial infarction 
was greater than a series of prespecified thresholds of 
harms. These probabilities were compiled from the pos-
terior distribution by repeated sampling using a func-
tion that took the value of 1 each time the summary 
adjusted odds ratio exceeded a given odds ratio thresh-
old, and took the value of 0 otherwise.38
Bayesian analyses were performed using JAGS39  (ver-
sion 3.4.0) and R40  (version 3.0.3; Foundation for Statis-
tical Computing). All Markov Chain Monte Carlo 
simulations were run on two chains with 10 000 itera-
tions, discarding the first 1000. Convergence was moni-
tored using CODA41  (version 0.16-1) and checked by 
observing the traces of posterior samples, and by 
inspecting the Gelman-Rubin R statistic42  and the Raf-
tery-Louis diagnostics.43 We assessed the heterogeneity 
of effects of NSAID use by examining the medians of 
between study standard deviation. Web appendix 3 pro-
vides additional information on the statistical analysis.
sensitivity and exploratory analyses
Heterogeneity
In sensitivity analyses for modelling the heterogeneity 
that may exist between studies, we considered three 
alternative prior distributions for the between study 
standard deviation on the log odds ratio, τ. These alter-
natives were one less informative half normal prior 
allowing for an eightfold variation in the odds ratios 
and two uniform priors equally supporting all values of 
τ and representing approximately twofold and fourfold 
variation in odds ratios of acute myocardial infarction 
across the four studies, respectively.
In exploratory analysis, we compared different drug 
use categories by calculating the bayesian posterior 
probability that summary adjusted odds ratios of acute 
myocardial infarction associated with a given NSAID 
exceeded those for another NSAID.38
Risk of bias
To examine how imperfect adjustment resulting from 
systematically missing confounders might affect esti-
mates of acute myocardial infarction, we used two 
adjustment strategies. We compared results of the 
RAMQ study obtained with the full set of 18 IPD 
meta-analysis confounders with only the six common 
IPD meta-analysis confounders.
patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
developing plans for design or implementation of the 
study. No patients were asked to advise on interpreta-
tion or writing up of results. There are no plans to dis-
seminate the results of the research to study participants 
or the relevant patient community. Our results may be 
shared through patient and public involvement initia-
tives established by developers of clinical practice 
guidelines discussing the use of NSAIDs.
Results
The pooled data comprised 61 460 cases and 385 303 
controls for a total number of 446 763 individuals. 
Table 1 gives the prevalence of IPD meta-analysis con-
founders at the index date in each study, which con-
firms that the populations differed. Despite differences 
in patient age, the RAMQ and Saskatchewan studies 
share a high prevalence of hyperlipidaemia and hyper-
tension diagnoses. This suggests that geographical 
table 1 | prevalence of confounders for association between exposure to non-steroidal anti-inflammatory drugs and acute myocardial infarction 
outcome at index date documented in each healthcare database study. values are numbers (percentages) unless stated otherwise
Confounders ramQ (n=233 816) Finland (n=172 219) gprD (n=17 561) saskatchewan (n=23 167)
Mean (SD) age at index date (years) 77.8 (6.1) 68.9 (12.7) 70.2 (11.5) 58.1 (12.8)
Median (interquartile range) age at index date (years) 78 (73-83) 70 (60-78) 71 (62-79) 56 (47-69)
Male sex 118 492 (50.7) 107 225 (62.3) 10 349 (58.9) 11 831 (51.1)
Comorbidities:
 Diabetes 40 812 (17.5) 12 911 (7.5) 1933 (11.0) 1663 (7.2)
 Hyperlipidaemia 72 008 (30.8) 19 212 (11.2) 2397 (13.7) 6738 (29.1)
 Hypertension 108 916 (46.6) 44 702 (26.0) 5944 (33.9) 9181 (39.6)
 Previous myocardial infarction 17 025 (7.3) NA NA 1154 (5.0)
 Coronary heart disease 79 466 (34.0) 29 998 (17.4) 3731 (21.3) 4972 (21.5)
 Congestive heart failure 19 602 (8.4) NA NA 1722 (7.4)
 Cerebrovascular disease 22 203 (9.5) NA 1480 (8.4) 1798 (7.8)
 Peripheral vascular disease 15 833 (6.8) NA NA 706 (3.1)
 Chronic obstructive pulmonary disease 53 465 (22.9) NA NA 2546 (11.0)
 Gastrointestinal ulcer disease 68 062 (29.1) NA NA 9419 (40.7)
 Gastrointestinal bleed 5686 (2.4) NA NA 1039 (4.5)
 Acute or chronic renal failure 4102 (1.8) NA NA 148 (0.6)
 Rheumatoid arthritis 4245 (1.8) 5180 (3.0) 574 (3.3) 1277 (5.5)
Concomitant drug treatment:
 Oral corticosteroids 5301 (2.3) NA NA NA
 Clopidogrel 4007 (1.7) 172 (0.1) NA NA
 Cardioprotective aspirin 53 738 (23.0) NA NA NA
NA=systematically missing in original study.
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 variations in medical practice and in population health 
contributed to observed differences in baseline charac-
teristics between Canadian and European studies. Spe-
cific strategies applied in the assessment of 
comorbidities may also explain some of the observed 
differences in prevalence between studies from health-
care databases.
Table 2 reports the adjusted odds ratios of acute myo-
cardial infarction for past use, recent use, and the five 
dose duration categories of current non-steroidal 
anti-inflammatory drug (NSAID) use compared with 
non-use of any NSAID in the year before the index date 
for each study and for the pooled studies. The results 
suggest that current NSAID use is associated with 
increased risks of acute myocardial infarction.
The plots on the left in figure 2 present the posterior 
probability of exceeding certain risk thresholds for each 
NSAID in each category of current use. The displayed 
plots help making a conclusion about degrees of harms 
of greater magnitude associated with current use of 
each NSAID.
The forest plots on the right in figure 2 present the 
summary adjusted odds ratios of acute myocardial 
infarction in the IPD meta-analysis, by drug for each 
multidimensional exposure category. Odds ratio point 
estimates of acute myocardial infarction for current use 
indicate an associated increase in risk of 20% to 50% 
overall, with possible increases of 75% for ibuprofen 
and naproxen and more than a 100% increase for 
rofecoxib. Credible intervals reveal that uncertainty 
about the extent of increased risk is greatest for ibupro-
fen and naproxen.
Table 3 shows the probability of increased risk of 
myocardial infarction (ie, the probability that the sum-
mary adjusted odds ratio of acute myocardial infarction 
is >1.0) with current use of a given NSAID, dose level, 
and duration of use. The probability of increased risk of 
myocardial infarction associated with use of an NSAID 
for one to seven days is 92% to 99%.
Onset of risk
The IPD meta-analysis suggests that the risk of myocar-
dial infarction associated with NSAID use increases 
immediately with exposure. This is illustrated by the 
position of the gold line in the plots in figure 2, 
which corresponds to the relevant NSAID use for one to 
seven days.
Dose effect
The IPD meta-analysis found a relation between 
increasing NSAID daily dose and risk of acute myocar-
dial infarction. The effect of the higher dose level is 
illustrated by the higher relative position of the red line 
(current use at high dose for 8-30 days) or the blue line 
(current use at high dose for >30 days) or both of these 
lines on graphs in the plots of figure 2 . This dose effect 
is also read from table 3  (last column), which shows a 
greater probability of the odds ratios of myocardial 
infarction being more than 50% at the higher dose level. 
With use for 8-30 days (red and brown lines in fig 2 ), a 
dose-risk relation is especially noticeable for rofecoxib 
but is also seen with naproxen and ibuprofen. With use 
for more than 30 days (blue and lavender lines in fig 2) 
a dose effect is again observed with rofecoxib and ibu-
profen but is no longer distinguishable with naproxen. 
With diclofenac and celecoxib, more modest dose 
effects are seen.
effect of duration of current use
In the IPD meta-analysis, a longer duration of treat-
ment generally does not seem to be associated with 
greater probabilities of increased risk of myocardial 
infarction. Visually, this is indicated by the lower posi-
tion of the lavender line (current use at low dose for 
>30 days) or the blue line (current use at high dose for 
>30 days) or both of these lines relative to the red, gold, 
or brown lines (≤30 days) in figure 2. Thus, with the 
possible exception of diclofenac, there are no obvious 
further increases in associated risk of myocardial 
infarction beyond one month compared with use for 
one month or less.
recency of use
The risk of acute myocardial infarction decreases 
over time since the last use of a NSAID, as shown by 
odds ratios of acute myocardial infarction for recent 
use at any dose and past use at any dose categories in 
figure 2.
Confidence in magnitude of risk increase associated 
with short term use
We examined the plots of bayesian posterior probability 
that summary adjusted odds ratios of acute myocardial 
infarction were greater than a series of prespecified 
thresholds. Selecting a benchmark of 80% (horizontal 
black line) and considering use for one to seven days 
(intersecting gold line), there was at least 80% proba-
bility that the odds ratio of acute myocardial infarction 
is greater than 1.07 for celecoxib, 1.30 for diclofenac and 
naproxen, 1.25 for ibuprofen, and 1.35 for rofecoxib 
(fig  2 ). Clinicians may wish to consider different cut 
points for posterior probability of risk and odds ratio 
thresholds. For example, with 750 mg/day or less of 
naproxen for 8-30 days, there is a 58% probability that 
the odds ratio of acute myocardial infarction is greater 
than 1.20 (brown line in fig 2).
heterogeneity of effects
Values of the between study standard deviations on the 
log odds ratio summarised across exposure categories 
had a mean of 0.100 and a median of 0.108 in the pri-
mary analysis. For a given category of NSAID use, the 
odds ratios are similar in magnitude across studies. 
This indicates good robustness despite populations 
being heterogeneous and duration of drug use and dose 
being constructed based on differing sources of raw 
data. Differences existed in matching strategies and in 
local prescribing habits during the study period, includ-
ing uptake of selective COX 2 inhibitors in the various 
study jurisdictions.44-46  These differences may explain 
the observed contrasting prevalences of exposure on 
index date within and between studies (table 2).
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sensitivity and exploratory analyses
Table 1 in web appendix 3 reports the results of sensitiv-
ity analyses according to selected priors for modelling 
between study heterogeneity. For a given NSAID cate-
gory, the posterior median for the summary adjusted 
odds ratios was relatively consistent across priors. 
Thus, all four analyses led to similar inferences. Results 
of model diagnostics indicate that convergence was 
achieved.
Few consistent patterns emerge in comparisons of 
NSAIDs based on probability that summary adjusted 
odds ratios of acute myocardial infarction with a given 
drug exceeded those for another, except that rofecoxib 
is associated with more cardiotoxicity than traditional 
NSAIDs (diclofenac, ibuprofen, and naproxen) and 
celecoxib (see fig 3 in web appendix 3).
In the sensitivity analysis for imperfect confounding 
adjustment based on the RAMQ study, only adjusting 
for the six common IPD meta-analysis confounders had 
a limited effect on the estimates obtained when adjust-
ing for the full set of 18 IPD meta-analysis confounders 
(see table 2 in web appendix 3). For exposures and con-
founders that are completely missing from the IPD 
meta-analysis common structure, we considered an 
alternative assumption that these were missing at ran-
dom and could be obtained by multiple imputation.47 48 
We concluded this was implausible in the context of 
observational studies sourced from healthcare data-
bases (see web appendix 3).
discussion
Through its inclusion and exclusion criteria and the 
definition of exposures, this meta-analysis of individual 
patient data (IPD) aimed to emulate the design of a 
large, pragmatic randomised trial49 comparing the 
main non-steroidal anti-inflammatory drugs (NSAIDs) 
used in the general population. By studying 61 460 myo-
cardial infarction events in real world use of NSAIDs, we 
found that current use of a NSAID is associated with a 
significantly increased risk of acute myocardial infarc-
tion. This was observed for all traditional NSAIDs, 
including naproxen. In this IPD meta-analysis, the risks 
of acute myocardial infarction for celecoxib do not 
appear to be greater than those for traditional NSAIDs 
and are lower than those for rofecoxib.
NSAIDs exhibited a rapid onset of risk for myocardial 
infarction in the first week of use. Use for 8-30 days at a 
high dose was particularly harmful for ibuprofen 
(>1200 mg/day), naproxen (>750 mg/day), and rofecoxib 
(>25 mg/day) (table 3  and red line in fig 2 ). The deple-
tion of susceptibles effect50  is a possible explanation for 
the spikes in risk observed with all NSAIDs. For cele-
coxib and diclofenac, a single wave of acute myocardial 
infarction cases occurred within one week (table 3 , 
fig 2 ). For ibuprofen, naproxen, and rofecoxib, there 
was additionally a subsequent wave of myocardial 
infarction cases taking place within 8-30 days of use at 
a high dose (table 3 , fig 2 , and fig 4 in web appendix 3). 
With longer term (>30 days) use of NSAIDs the risk of 
myocardial infarction may not appear greater for that 
observation period (except maybe for diclofenac, fig 2 ). ta
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This may be because those more susceptible to acute 
myocardial infarction were selected out of the cohort at 
earlier time points. Quantitative differences among 
NSAIDs in terms of blood pressure increases or deterio-
ration of renal function (such as those reported in the 
Prospective Randomized Evaluation of Celecoxib Inte-
grated Safety vs. Ibuprofen Or Naproxen (PRECISION) 
trial),5 might contribute to this depletion of susceptibles 
effect.
Our findings suggest that the risks of myocardial 
infarction associated with rofecoxib are greater than 
those associated with other NSAIDs (fig 2). This feature 
may explain why the myocardial infarction risk of 
NSAIDs was uncovered first through rofecoxib trials. 
Our study suggests a smaller risk of myocardial infarc-
tion exists with all other NSAIDs.
strengths and weaknesses of this study
Patient level meta-analysis has the specific advantages 
of improving the coherence of exposure definitions, 
allowing more consistent adjustment for confounding 
and accounting for variations over time of exposure and 
confounder status.51  Our work, which draws on large 
population based cohorts created from administrative 
health or medical databases, is an innovative applica-
tion of IPD meta-analysis for studying a drug related 
adverse event. Access to granular data allowed for more 
comprehensive evaluation of whether or not studies 
were sufficiently comparable for pooling, which is not 
possible for aggregate based meta-analysis.52 Data har-
monisation reduced the bias due to misclassification of 
NSAID exposure. Through finely restricted time win-
dows after start of treatment, we could discern succes-
sive occurrences of depletion of susceptibles effect and 
document dose effects and the time course of risk for 
acute myocardial infarction.
The bayesian approach is useful for decision making. 
Take, for example, the summary odds ratio of acute 
myocardial infarction of 2.65 (1.46 to 4.67) with rofecoxib 
>25 mg/day for 8-30 days versus non-use. With a fre-
quentist confidence interval, which represents uncer-
tainty through repetition of the experience, all odds 
ratios from 1.46 to 4.67 might seem equally likely. In 
contrast, the bayesian approach, although resulting in 
a numerically similar 95% credible interval, also allows 
us to calculate that there is an 83% probability that this 
odds ratio of acute myocardial infarction is greater than 
2.00. Because of the underlying low between study het-
erogeneity, information was effectively shared by stud-
ies (table 2), allowing more definitive conclusions to be 
reached.
The common practice in aggregate data meta-analy-
sis is to pool studies irrespective of internal validity, and 
perhaps to conduct sensitivity analyses based on qual-
ity. We opted to assess whether or not candidate studies 
were adequate at the IPD meta-analysis design stage. 
This offered important gains in efficiency, improved the 
control of confounding, and minimised measurement 
error. Indeed, given the objectives of this meta-analysis, 
not excluding studies with misclassified exposure time 
or with incompatible exposure definitions might have 
induced information bias. Figures 2 to 6 in web appen-
dix 1, created after study selection, suggest this 
approach was an acceptable trade-off and did not lead 
to biased selection of studies.
Of eight eligible studies, four ultimately had to be 
excluded because of ethicolegal restrictions placed by 
health authorities on transfer of IPD to third parties. 
Selection bias, denoting a common effect of two vari-
ables,53 was not expected to occur since denied access 
to patient level data was completely independent of 
findings of acute myocardial infarction in the study. 
Figs 2 to 6 in web appendix 1 show that the unavailabil-
ity of four studies did not result in bias. However, 
unavailability did reduce statistical power, affecting the 
precision around estimates of myocardial infarction 
risk in the IPD meta-analysis.
This work shares the limitations of all studies sourced 
from databases, which measure drug dispensing or 
drug prescribing and not actual drug intake. In particu-
lar, the ibuprofen estimates may be globally more frag-
ile due to the universal availability of over-the-counter 
table 3 | probability that risk of acute myocardial 
infarction is increased (odds ratio >1.0) and probability of 
this risk increase being greater than 50% (odds ratio 
>1.5) according to dose and duration of non-steroidal 
anti-inflammatory drug use
Current use category
bayesian posterior 
probability (%) of 
summary adjusted 
odds ratio of acute 
myocardial infarction
>1.0 >1.5
Celecoxib:
 Any dose for ≤7 days 92.4 12.1
 ≤200 mg/day for 8-30 days 97.4 6.3
 >200 mg/day for 8-30 days 85.8 12.5
 ≤200 mg/day for >30 days 97.9 1.8
 >200 mg/day for >30 days 95.0 8.0
Diclofenac:
 Any dose for ≤7 days 98.6 50.1
 ≤100 mg/day for 8-30 days 93.3 2.0
 >100 mg/day for 8-30 days 92.7 7.0
 ≤100 mg/day for >30 days 99.9 25.3
 >100 mg/day for >30 days 98.8 45.6
Ibuprofen:
 Any dose for ≤7 days 97.3 47.1
 ≤1200 mg/day for 8-30 days 59.3* 0.6*
 >1200 mg/day for 8-30 days 97.5 70.8
 ≤1200 mg/day for >30 days 98.0 14.5
 >1200 mg/day for >30 days 98.3 45.3
Naproxen:
 Any dose for ≤7 days 98.8 54.9
 ≤750 mg/day for 8-30 days 92.1 7.3
 >750 mg/day for 8-30 days 99.2 77.2
 ≤750 mg/day for >30 days 94.9 3.0
 >750 mg/day for >30 days 91.6 5.0
Rofecoxib:
 Any dose for ≤7 days 98.8 63.6
 ≤25 mg/day for 8-30 days 88.6 14.0
 >25 mg/day for 8-30 days 99.8 96.9
 ≤25 mg/day for >30 days 99.9 9.0
 >25 mg/day for >30 days 99.0 59.3
*Sparse data.
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purchase and because use “as needed” in our data was 
documented to be more prevalent for ibuprofen than for 
the other NSAIDs.
Previous papers54 55  provide useful insight on the risk 
of bias due to confounders unobserved in studies from 
databases (obesity, over-the-counter aspirin or NSAID 
use, smoking, income, or educational attainment), 
which suggests that failure to adjust for these con-
founders might slightly underestimate the risk of myo-
cardial infarction.56  We suspect that residual 
confounding exists because substantive knowledge57-59 
ascertains that there are mediating intermediate vari-
ables on the causal pathway between NSAID exposures 
and acute myocardial infarction (see fig 1 in web appen-
dix 2). Analyses of the PRECISION trial5  suggest that the 
main sources of bias from residual confounding in our 
study are the mediating effects of blood pressure 
increases or renal deterioration. The likelihood of bias 
may increase with longer durations of NSAID use over 
follow-up time, such that the odds ratios of acute myo-
cardial infarction in the exposure categories corre-
sponding to use for longer than 30 days might be biased 
to the null (underestimated). On the basis of our assess-
ment of the literature23 26 60 and the anticipated direc-
tion of bias to the null, we believe that unmeasured and 
incompletely measured confounders are unlikely to 
affect the substantive conclusions of this IPD meta-anal-
ysis, which found associations between current NSAID 
use and increased risk of acute myocardial infarction.
Comparison with other studies
The patients enrolled in the PRECISION randomised 
controlled trial required regular daily NSAID treatment 
for arthritis and received rather high doses of ibuprofen 
(2045 (SD 246) mg) and naproxen (852 (103) mg). Per-
mitted doses of celecoxib (209 (37) mg) were at the 
low-moderate end of the therapeutic range. The results 
of this IPD meta-analysis of studies from healthcare 
databases are aligned with the main conclusions of the 
PRECISION trial, which concluded that in studied dos-
ages, celecoxib was non-inferior to ibuprofen or 
naproxen for cardiovascular safety.5 Similar to our 
observational findings, the PRECISION trial does not 
provide evidence to suggest that naproxen is safer than 
other NSAIDs.
Summaries of risk for acute myocardial infarction 
with NSAIDs obtained in placebo controlled trials are 
available from two network meta-analyses, one with 
aggregate data4  and the other with IPD.3  The bulk of 
placebo controlled direct evidence suggesting a neutral 
effect for naproxen came from randomised controlled 
trials in populations with, or at risk of, Alzheimer’s 
 disease.4  Non-adherence bias, documented in such 
patient populations,61  may translate into an underesti-
mation of the risk with naproxen in meta-analyses of 
randomised controlled trials. The risk of myocardial 
infarction was not considered separately for the various 
selective COX 2 inhibitors in the IPD network meta-anal-
ysis of randomised controlled trials.3  Our results indi-
cate that there seem to be differences between rofecoxib 
and celecoxib on risk of acute myocardial infarction, 
which agrees with the findings for celecoxib in the PRE-
CISION trial.5
Estimates of risks for acute myocardial infarction 
found by the Safety of Non-Steroidal Anti-Inflamma-
tory (SOS) Project meta-analysis of observational 
studies36  are overall lower than those of our IPD 
meta-analysis. In accordance with most aggregate 
meta-analyses, no restriction based on methodologi-
cal quality was imposed in the SOS meta-analysis 
such that it included field case-control studies possi-
bly affected by recall bias,62 63  a cohort study with 
immortal time bias,64  studies that compared risk in 
current users with users in the recent past,54 65  and 
studies defining as current use a time window possi-
bly remote from the event date.66 67 These dissimilari-
ties and potential biases, if occurring in a 
non-differential manner, would be expected to move 
pooled odds ratio of acute myocardial infarction 
towards the null (see figs 2 to 6 in web appendix 1).
In the Adenomatous Polyp Prevention on Vioxx 
(APPROVe) trial, the largest individual trial of rofecoxib 
(25 mg) versus placebo, the hazard ratio of acute myo-
cardial infarction up to 14 days after end of treatment 
was 2.65 (95% confidence interval 1.21 to 5.75).68  The 
Trelle network meta-analysis of randomised controlled 
trials reported a rate ratio for rofecoxib (any daily dose) 
versus placebo of 2.12 (95% credible interval 1.26 to 
3.56).4  A weighted average of the IPD meta-analysis 
findings across the five categories of current rofecoxib 
use (see table 2  and fig 2) would yield a lower risk than 
that of the APPROVe trial and the Trelle network 
meta-analysis of randomised controlled trials.
unanswered questions and future research
We might have taken advantage of this study to investi-
gate clinical heterogeneity using a formal analysis of 
interactions between NSAIDs and major cardiovascular 
risk profiles.69-71  However, interaction studies involving 
a categorical NSAID exposure, such as in this IPD 
meta-analysis, would have less statistical power72  and 
would overly depend on classifying drug exposure 
without error.73
Since methods exist for pooling IPD and aggregate 
data 51  we considered performing a combined IPD 
aggregate data meta-analysis. This proved infeasible 
because the aggregate data did not permit reconstruc-
tion of NSAID exposure as multidimensional categori-
cal variables or adjustment for time dependence of 
confounders. In our experience, a particular and possi-
bly underappreciated hurdle of IPD meta-analysis 
sourced from healthcare databases is that they critically 
depend on health authorities granting permission to 
access IPD. This lack of willingness to share even 
deidentified observational data is in direct contrast to 
the current movement to encourage data sharing of ran-
domised controlled trials74 and is a potential barrier to 
improving comparative effectiveness research.
Even a set of exposure indicators combining recency 
of use, dose, and duration of treatment, may not suffice 
to precisely describe the joint impact on myocardial 
infarction of all components of exposure we assessed in 
the bmj | BMJ 2017;357:j1909 | doi: 10.1136/bmj.j1909
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this IPD meta-analysis. In particular, we could not 
study whether the effect of past doses of NSAIDs per-
sisted and affected current risk nor could we determine 
the precise onset of any associated increased risk or the 
exact duration of any persistence of risk after stopping 
an NSAID. In particular, for diclofenac, the risk of myo-
cardial infarction with treatment for more than 30 days 
(blue and lavender lines in fig 2  and table 3 ) is higher 
than with treatment for 8-30 days (brown and red lines 
in fig 2 ), which hints at cumulative effects for this drug. 
A more sensitive modelling approach might be needed 
to finely ascribe risk—for example, after switching 
between NSAIDs. A recency weighted cumulative expo-
sure model75 76 might help answer these additional 
questions.
Conclusions and policy implications
This patient level meta-analysis of acute myocardial 
infarction associated with NSAIDs involving 61 460 
cases in 446 763 individuals is the largest investigation 
of its type, and its real world origin helps ensure that 
findings are broadly generalisable. The key advantages 
of this IPD meta-analysis are its pertinence of popula-
tions, power owing to sample size, relevance of expo-
sure measurement, and posterior probability 
distributions that directly inform clinical practice. That 
we were able to draw conclusions on the risk of myocar-
dial infarction of NSAID dose levels and treatment dura-
tions corresponding to various scenarios of actual use is 
a novel contribution.
In summary, compared with non-use of NSAIDs in 
the preceding year, we documented that current use of 
all studied NSAIDs, including naproxen, was associated 
with an increased risk of acute myocardial infarction. 
The risk of myocardial infarction with celecoxib was not 
found to exceed that of other NSAIDs and was lower 
than for rofecoxib. Given that the onset of risk of acute 
myocardial infarction occurred in the first week and 
appeared greatest in the first month of treatment with 
higher doses, prescribers should consider weighing the 
risks and benefits of NSAIDs before instituting treat-
ment, particularly for higher doses.
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